Piper Sandler maintains Overweight on NextCure with PT down to $15.
ByAinvest
Tuesday, Jul 15, 2025 10:52 am ET1min read
NXTC--
The reverse stock split is part of NextCure's ongoing efforts to improve its stock's liquidity and marketability. The company's shares have declined over 75% in the past year, trading below their InvestingPro Fair Value, suggesting potential upside opportunity [2]. Despite the decline, NextCure maintains a strong liquidity position with a current ratio of 10.26 and holds more cash than debt on its balance sheet [2].
NextCure is currently conducting a Phase I study of its B7-H4 ADC LNCB74 in breast, ovarian, and endometrial cancers, with data expected in the first half of 2026. The company also recently partnered with Simcere Zaiming for SIM0505, a CDH6-targeting ADC for solid tumors, in a deal worth up to $745 million in upfront and milestone payments, plus tiered royalties for territories outside China [2].
NextCure plans to initiate a Phase I study of SIM0505 in the United States this quarter, with initial data anticipated in the first half of 2026. The company is also seeking partners for its other assets. As of the first quarter of 2025, NextCure reported cash holdings of $55.9 million, which is expected to fund operations into the second half of 2026 [2].
Piper Sandler’s price target reduction reflects both the reverse stock split and a rolled-forward discount rate to mid-2026. The company's recent governance and strategic planning efforts, including the election of new directors and the ratification of an independent auditor, also contribute to the investment thesis [1].
References:
[1] https://www.investing.com/news/sec-filings/nextcure-announces-1for12-reverse-stock-split-effective-july-14-93CH-4130194
[2] https://www.investing.com/news/analyst-ratings/piper-sandler-lowers-nextcure-stock-price-target-to-15-after-reverse-split-93CH-4136029
PIPR--
Piper Sandler maintains Overweight on NextCure with PT down to $15.
Piper Sandler has lowered its price target on NextCure Inc. (NASDAQ:NXTC) to $15.00 from $36.00, while maintaining an Overweight rating on the stock. The adjustment follows NextCure’s 12-for-1 reverse stock split that became effective July 14. After the split, NextCure has approximately 2.338 million shares outstanding and a market capitalization of $11.5 million [2].The reverse stock split is part of NextCure's ongoing efforts to improve its stock's liquidity and marketability. The company's shares have declined over 75% in the past year, trading below their InvestingPro Fair Value, suggesting potential upside opportunity [2]. Despite the decline, NextCure maintains a strong liquidity position with a current ratio of 10.26 and holds more cash than debt on its balance sheet [2].
NextCure is currently conducting a Phase I study of its B7-H4 ADC LNCB74 in breast, ovarian, and endometrial cancers, with data expected in the first half of 2026. The company also recently partnered with Simcere Zaiming for SIM0505, a CDH6-targeting ADC for solid tumors, in a deal worth up to $745 million in upfront and milestone payments, plus tiered royalties for territories outside China [2].
NextCure plans to initiate a Phase I study of SIM0505 in the United States this quarter, with initial data anticipated in the first half of 2026. The company is also seeking partners for its other assets. As of the first quarter of 2025, NextCure reported cash holdings of $55.9 million, which is expected to fund operations into the second half of 2026 [2].
Piper Sandler’s price target reduction reflects both the reverse stock split and a rolled-forward discount rate to mid-2026. The company's recent governance and strategic planning efforts, including the election of new directors and the ratification of an independent auditor, also contribute to the investment thesis [1].
References:
[1] https://www.investing.com/news/sec-filings/nextcure-announces-1for12-reverse-stock-split-effective-july-14-93CH-4130194
[2] https://www.investing.com/news/analyst-ratings/piper-sandler-lowers-nextcure-stock-price-target-to-15-after-reverse-split-93CH-4136029
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet